



(51) International Patent Classification:

C07K 14/725 (2006.01) *A61K 47/68* (2017.01)
A61K 38/17 (2006.01) *C07K 19/00* (2006.01)
A61K 47/62 (2017.01) *C12N 15/12* (2006.01)

(21) International Application Number:

PCT/CA2021/051855

(22) International Filing Date:

21 December 2021 (21.12.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/128,601 21 December 2020 (21.12.2020) US

(71) Applicant: **ZYMEWORKS INC.** [CA/CA]; Suite 800 –
114 East 4th Avenue, Vancouver, British Columbia V5T
1G4 (CA).

(72) Inventors: **ESCOBAR-CABRERA, Eric**; 540-1385 West
8th Avenue, Vancouver, British Columbia V6H 3V9
(CA). **FREIBURGER, Lee**; 540-1385 West 8th Ave-
nue, Vancouver, British Columbia V6H 3V9 (CA). **PAT-
TON, Daniel T.**; 540-1385 West 8th Avenue, Vancouver,
British Columbia V6H 3V9 (CA). **PRESTA, Leonard G.**;
540-1385 West 8th Avenue, Vancouver, British Colum-
bia V6H 3V9 (CA). **FARBER, Patrick**; 540-1385 West
8th Avenue, Vancouver, British Columbia V6H 3V9 (CA).
STEVENS, Charles Michael; 540-1385 West 8th Avenue,
Vancouver, British Columbia V6H 3V9 (CA).

(74) Agent: **SALISBURY, Clare** et al.; Gowling WLG (Can-
ada) LLP, Suite 2300 - 550 Burrard Street, Vancouver,
British Columbia V6C 2B5 (CA).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,

(54) Title: STABILIZED TCR CONSTRUCTS AND METHODS OF USE




Fig. 2

(57) **Abstract:** Stabilized TCR constructs comprising a TCR alpha chain polypeptide having a variable alpha (V α) domain and a constant alpha (C α) domain and a TCR beta chain polypeptide having a variable beta (V β) domain and a constant beta (C β) domain. The TCR constructs are stabilized by the introduction into the C α domain and/or the C β domain of stabilizing mutations such as non-naturally occurring disulfide bonds between the C α domain and the C β domain (an interchain disulfide bond), non-naturally occurring intrachain disulfide bonds, point mutations, loop truncation mutations, and combinations thereof. TCR fusion proteins comprising one or more of the TCR constructs and a scaffold and/or other biologically active moiety are also described.

[Continued on next page]

HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE